Thymalin

Thymalin is a polypeptide complex isolated from calf thymus. Its key active sequences are the short peptides L-Glu-L-Trp (EW), Lys-Glu (KE), and Glu-Asp-Pro (EDP) ². In experimental and clinical research it acts as an immunomodulator rather than a general immune stimulant: the goal is to restore T-cell function and normalize cytokine and coagulation parameters in immunodepressed states ².

Human clinical study has focused on severe viral pneumonia and immune decline. The best-documented regimen is 10 mg intramuscularly once daily for 5 days as an add-on in severe COVID-19 ⁷. Historically the compound was used in Soviet-era medicine for immunodeficiencies, burns, surgical sepsis, and tuberculosis ². The related dipeptide L-Glu-L-Trp was later isolated from the complex and developed separately as Thymogen ¹⁵.

In simple terms, Thymalin appears to act as a gene-regulating signal rather than a surface receptor signal. Its short peptides KE (Lys-Glu), EW (Glu-Trp), and EDP bind double-stranded DNA and histone proteins, where they regulate expression of genes involved in immune-system protein production, aging-linked genes, and stem-cell differentiation ¹. Molecular docking studies suggest EW docks preferentially at one DNA sequence and KE at another, with predicted targets including genes involved in cytokine-storm signaling and blood-vessel regulation ³.

In human bone-marrow stem-cell cultures, Thymalin lowered markers of immature stem cells (CD44 and CD117) by roughly 2 to 3 times and raised the mature T-cell marker CD28 by 6.8-fold, moving early progenitors toward mature T-lymphocytes ⁴. At the same time, in immune cells challenged with an inflammatory stimulus, Thymalin and its dipeptides reduced secretion of IL-1β, IL-6, and TNF-α by 1.4 to 6.0 fold ³. This pattern is described as anti-inflammatory rather than broadly immunosuppressive ⁵.

Most human data are retrospective cohorts and case series, so effects are best read as measured changes rather than outcomes from large placebo-controlled trials ¹.

Severe COVID-19 immune recovery: In an 87-patient retrospective study, adding 10 mg intramuscularly once daily for 5 days to standard therapy predicted normalization of total lymphocytes, helper and cytotoxic T-cells, B-cells, and natural killer cells by day 6; basic therapy alone did not ⁷. In a comparative cohort, hospital mortality was 16.2 to 20.6 percent in the Thymalin arm versus 40.9 percent with standard therapy ⁸.

Inflammatory and clotting markers: Thymalin add-on was associated with faster declines in IL-6, C-reactive protein, D-dimer, and lactate dehydrogenase, and improved T-cell parameters ⁶.

More durable antibody memory: Anti-SARS-CoV-2 IgG declined only 21 percent by day 104 after Thymalin, versus 53 percent with standard therapy ¹⁰.

Bone and tissue repair: In rat mandibular defects, local Thymalin injection plus a bone graft accelerated debris clearance, early bone-forming cell response, and mineralization ¹⁸. In a rat chemotherapy model it increased dermal immune cells and preserved skin thickness ¹⁷.

Burns and dental disease: Small historical human studies reported faster graft timing, shorter hospital stay, and coagulation normalization in burns ²¹, and dental use is described for inflammatory maxillofacial conditions ²².

Aging and lifespan: In a 266-person cohort followed 6 to 8 years, Thymalin courses were associated with roughly 2.0 to 2.1 times lower mortality and lower acute respiratory disease incidence ¹⁴. Animal data with the EW dipeptide showed longer lifespan and lower tumor incidence ¹⁵.

Published human protocols use fixed 10 mg doses, most commonly intramuscularly once daily for 5 days ⁷. There is no published weight-stratified human dosing; the 10 mg schedule is the only human dose validated in the clinical literature ⁷.

Representative patterns in the source literature:

• Severe infection adjunct: 10 mg intramuscularly once daily for 5 days, added to standard therapy in COVID-19 cohorts ⁷.
• Longer immune restoration courses: Community protocols often extend the same schedule to 5 to 10 days, sometimes repeated 2 to 4 times per year (community practice, not a cited clinical trial).
• Body-weight anchors from animal studies: 0.1 mg/kg intramuscularly twice, 72 hours apart, cleared infection and restored immune parameters in cattle ²⁰; rats received 0.01 mg/day for 7 days ¹⁷.
• Geroprotection: The 266-person cohort used repeated courses over the first 2 to 3 years and, in one subgroup, annual combined courses for 6 years ¹⁴.

Route comparison: intramuscular is the only route with published human data ⁷. Subcutaneous use has no published human comparator, though the small-peptide complex would be expected to absorb well (mechanistic expectation). Local perilesional injection is studied only in animal bone-defect models ¹⁸. Oral administration has no published support.

Thymalin is supplied as a lyophilized powder, with 10 mg per vial the standard presentation in research and clinical practice ⁷. The active components are short peptides, including EW, KE, and EDP ².

Diluent choice is straightforward: bacteriostatic water (0.9 percent benzyl alcohol) is the common research diluent; sterile water for injection is acceptable when the solution is used immediately. Mixing should be gentle: add the diluent down the vial wall and swirl, rather than shake.

Qualitative storage guidance from standard peptide handling: keep lyophilized powder refrigerated at 2 to 8°C, or frozen for longer-term storage, protected from light and moisture. After reconstitution, keep the solution refrigerated and use within about 14 to 28 days, or within 24 hours when sterile non-bacteriostatic water is used. Avoid repeated freeze-thaw cycles and discard any solution that is cloudy or contains particles. Published forced-degradation studies are sparse, so standard lyophilized-peptide handling is applied.

The interactive calculator below works through the dilution math for any vial size, diluent volume, and research dose.

Documented and theoretical interactions center on immune and coagulation pathways.

Corticosteroids: In severe COVID-19 cohorts, Thymalin was added to dexamethasone-containing standard therapy without an adverse interaction signal, and immune recovery occurred where standard therapy alone did not ⁷.

Tocilizumab and IL-6 biologics: Mechanisms differ; in a retrospective comparison the Thymalin arm had lower hospital mortality than the tocilizumab arm, and case reports describe improvement when Thymalin was added after tocilizumab failure ⁸.

Anticoagulants and antiplatelets: Thymalin normalizes hypercoagulation by lowering fibrinogen and D-dimer, so combined use with blood thinners carries a theoretical additive bleeding risk. Coagulation monitoring is emphasized in the source material ⁸.

Thyroid hormones: Thyroid status modifies Thymalin's pharmacodynamic effect in animal and human studies, so thyroid function should be stabilized before use ³⁰.

Antibiotics: Antibiotic plus Thymalin was efficacy-additive in veterinary mycoplasma infection and chronic ear infection ²⁰.

Immunosuppressants: The theoretical direction is mutual opposition, because Thymalin drives T-cell reconstitution ⁴.

Vaccines: Thymalin was associated with slower decline of anti-SARS-CoV-2 IgG after infection, suggesting a possible IgG-sparing effect rather than vaccine interference ¹⁰.

Thymalin is used in short courses and repeated intermittently rather than continuously. The rationale in the research is that it restores immune parameters to normal rather than chronically overstimulating them, and once normalization occurs further dosing has no clear added signal ².

Effects outlast the dosing window. A single 5-day COVID-19 course was associated with better preservation of anti-SARS-CoV-2 IgG at day 104, so off-periods are used to see whether restored immunity holds ¹⁰. In the 266-person geroprotection cohort, treatment was given for the first 2 to 3 years, with a subgroup using annual courses for 6 years, which produced the largest mortality reduction ¹⁴.

Community practice commonly runs 5 to 10 day courses a few times per year, with breaks between courses and restarts timed to respiratory season or planned immune stress. The published literature describes practically no side effects and no documented withdrawal syndrome, so cycling is driven by diminishing returns rather than toxicity ². No human study supports continuous daily dosing.

Thymalin plus Epithalon: The best-documented pairing. In the 266-person cohort, Thymalin plus Epithalamin reduced mortality more than either peptide alone; the 6-year annual-combination subgroup showed a 4.1-fold reduction versus control ¹⁴. Community protocols sometimes pair thymic and pineal peptides for immune and circadian support.

Thymalin plus Thymogen (EW): Redundant for immune purposes, because L-Glu-L-Trp is one of the active components isolated from Thymalin itself ³. Research protocols generally choose one rather than both.

Thymalin plus other Khavinson peptides: In monocyte studies, Thymalin, Vilon, Epitalon, and Chonluten together suppressed TNF and IL-6 and reduced leukocyte adhesion to activated endothelium, providing a mechanistic basis for multi-peptide anti-inflammatory stacks ⁵.

Thymalin plus repair peptides (BPC-157, TB-500): No direct co-administration data exist, but the mechanisms are distinct; community reports and practitioner practice commonly co-administer immune and tissue-repair peptides without conflict signals.

Thymalin plus Thymosin Alpha-1: Functional overlap on T-cell maturation, so research protocols generally treat them as alternatives rather than a stack ⁴.

Thymalin is a registered medicinal product in Russia and related countries, where it has decades of clinical use as an immunomodulator ². It is not FDA-approved, and no US marketing authorization exists. It is not scheduled by the US DEA.

Most Western jurisdictions treat it as an unapproved research peptide. The EU, UK, and Australia have no marketing authorization, and personal import of unapproved injectable peptides is restricted or prohibited in most Western jurisdictions.

For competitive athletes, Thymalin is not named on the WADA Prohibited List, but it may fall under the S0 category for non-approved substances, which prohibits substances without government approval for human therapeutic use. Athletes should treat it as a prohibited-at-all-times risk substance under current antidoping frameworks.

Thymalin is described in the review literature as having practically no side effects ². In severe COVID-19 cohorts treated with 10 mg intramuscularly daily for 5 days, no drug-attributed adverse events were reported; the documented lab changes were therapeutic normalizations ⁷.

The most common observed shifts are increases in lymphocytes, monocytes, leukocytes, and platelets from depleted baselines, plus reductions in elevated fibrinogen, D-dimer, and LDH. These represent restoration of suppressed immune and clotting compartments rather than overstimulation ⁸.

Relevant cautions:

• Anticoagulant use: Theoretical additive bleeding risk because Thymalin lowers fibrinogen and D-dimer; coagulation parameters should be checked ⁸.
• Thyroid dysfunction: Altered pharmacodynamics are documented in hypo- and hyperthyroid states ³⁰.
• Autoimmune disease: T-cell activation makes autoimmune flare a theoretical risk, though no events were reported in a 6 to 8 year cohort ⁴.
• Pregnancy and breastfeeding: No human reproductive-safety data exist, so use is unsupported outside clinical supervision.
• Injection-site reactions: Community reports describe transient soreness and, in some users, brief sleepiness at treatment onset; no systematic patient-reported outcome data exist.